Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Cara Therapeutics (CARA) Stock Price & Analysis
2,235 Followers
CARA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.24 - $3.45
Previous Close$0.34
Volume1.02M
Average Volume (3M)887.42K
Market Cap
$18.64M
Enterprise Value-$44.08M
Total Cash (Recent Filing)$69.77M
Total Debt (Recent Filing)$7.04M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 05, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.25
Shares Outstanding54,675,954
10 Day Avg. Volume1,592,908
30 Day Avg. Volume887,425
Standard Deviation0.19
R-Squared0.05
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.18
Price to Sales (P/S)0.72
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.37
Enterprise Value/Gross Profit-2.10
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$1.00Price Target Upside193.26% Upside
Rating ConsensusHold
Number of Analyst Covering5
Cara Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market OpportunityNotalgia paresthetica affects approximately 650,000 patients in the US, presenting a projected market opportunity of over $300 million with no current FDA-approved therapies.
Stock ValuationThere is a highly positive risk-reward with Cara currently trading at around 0.5 times cash, making it an attractive investment ahead of the anticipated trial results.
Trial Data AnnouncementCARA plans to announce data from the Part A dose-finding portion of the Ph2/3 KOURAGE-1 trial in notalgia paresthetica, a condition with no FDA-approved drugs, which could significantly impact the stock.
Bears Say
Clinical TrialsCara's last clinical shot on goal for oral difelikefalin failed to demonstrate meaningful clinical benefit vs. placebo.
Financial PerformanceWith $70mn in cash, CARA no longer has sufficient resources for further exploration and is winding down the Ph.2/3 clinical program.
Market ProspectsU.S.-partnered IV Korsuva commercial prospects are dim following draconian CMS bundled reimbursement.
---
Ownership Overview
15.96% Insiders
16.05% Mutual Funds
5.17% Other Institutional Investors
62.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CARA FAQ
What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $0.24 and its highest was $3.45 in the past 12 months.
What is Cara Therapeutics’s market cap?
Currently, no data Available
When is Cara Therapeutics’s upcoming earnings report date?
Cara Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 18 days.
How were Cara Therapeutics’s earnings last quarter?
Cara Therapeutics released its earnings results on May 13, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.398 by -$0.162.
Is Cara Therapeutics overvalued?
According to Wall Street analysts Cara Therapeutics’s price is currently Undervalued.
Does Cara Therapeutics pay dividends?
Cara Therapeutics does not currently pay dividends.
What is Cara Therapeutics’s EPS estimate?
Cara Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Cara Therapeutics have?
Cara Therapeutics has 54,675,953 shares outstanding.
What happened to Cara Therapeutics’s price movement after its last earnings report?
Cara Therapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.398. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Cara Therapeutics?
Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 1M.
---
Cara Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (193.26% Upside)
$1.00 (193.26% Upside)
Hedge Fund Trend
Decreased
By 17.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.11%
12-Months-Change
Fundamentals
Return on Equity
-147.29%
Trailing 12-Months
Asset Growth
-41.22%
Trailing 12-Months
Company Description
Cara Therapeutics
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
---
CARA Earnings Call
Q4 2024
0:00 / 0:00
---
CARA Stock 12 Month Forecast
Average Price Target
$1.00
▲(193.26% Upside)
Technical Analysis
Best Analysts Covering CARA
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+84.97%
reiterated a sell rating 11 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +84.97% per trade.
---